These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25583785)

  • 21. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma.
    Chmielewski M; Hombach AA; Abken H
    Immunol Rev; 2014 Jan; 257(1):83-90. PubMed ID: 24329791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic engineering of T cells in leukemia and lymphoma.
    Kochenderfer JN
    Clin Adv Hematol Oncol; 2014 Mar; 12(3):190-2. PubMed ID: 24927269
    [No Abstract]   [Full Text] [Related]  

  • 23. Engineering T-cells with antibody-based chimeric receptors for effective cancer therapy.
    Thistlethwaite F; Mansoor W; Gilham DE; Hawkins RE
    Curr Opin Mol Ther; 2005 Feb; 7(1):48-55. PubMed ID: 15732529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells.
    Ramachandran M; Dimberg A; Essand M
    Semin Cancer Biol; 2017 Aug; 45():23-35. PubMed ID: 28257957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Next Steps in the CAR Journey of a Thousand Miles.
    Brenner MK
    Mol Ther; 2017 Oct; 25(10):2226-2227. PubMed ID: 28939089
    [No Abstract]   [Full Text] [Related]  

  • 26. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
    Weibo P; Zhaoming Y
    Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in CAR T-cell therapy for chronic lymphocytic leukemia.
    Porter DL
    Clin Adv Hematol Oncol; 2018 Feb; 16(2):118-120. PubMed ID: 29741512
    [No Abstract]   [Full Text] [Related]  

  • 28. TCR diversity - a universal cancer immunotherapy biomarker?
    McNeel DG
    J Immunother Cancer; 2016; 4():69. PubMed ID: 27879971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFNγ.
    Textor A; Listopad JJ; Wührmann LL; Perez C; Kruschinski A; Chmielewski M; Abken H; Blankenstein T; Charo J
    Cancer Res; 2014 Dec; 74(23):6796-805. PubMed ID: 25297631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer.
    Duong CP; Westwood JA; Berry LJ; Darcy PK; Kershaw MH
    Immunotherapy; 2011 Jan; 3(1):33-48. PubMed ID: 21174556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells.
    Kawalekar OU; O'Connor RS; Fraietta JA; Guo L; McGettigan SE; Posey AD; Patel PR; Guedan S; Scholler J; Keith B; Snyder NW; Blair IA; Milone MC; June CH
    Immunity; 2016 Feb; 44(2):380-90. PubMed ID: 26885860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CAR mechanics: driving T cells into the MUC of cancer.
    Maher J; Wilkie S
    Cancer Res; 2009 Jun; 69(11):4559-62. PubMed ID: 19487277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy.
    Karlsson H; Lindqvist AC; Fransson M; Paul-Wetterberg G; Nilsson B; Essand M; Nilsson K; Frisk P; Jernberg-Wiklund H; Loskog A
    Cancer Gene Ther; 2013 Jul; 20(7):386-93. PubMed ID: 23788110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Engineered cell therapy for cancer gets thumbs up from FDA advisers.
    Ledford H
    Nature; 2017 Jul; 547(7663):270. PubMed ID: 28726836
    [No Abstract]   [Full Text] [Related]  

  • 35. Current status of genetic modification of T cells for cancer treatment.
    Dotti G; Heslop HE
    Cytotherapy; 2005; 7(3):262-72. PubMed ID: 16081353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perspective: assembly line immunotherapy.
    Levine BL; June CH
    Nature; 2013 Jun; 498(7455):S17. PubMed ID: 23803946
    [No Abstract]   [Full Text] [Related]  

  • 37. Improving the efficacy and safety of engineered T cell therapy for cancer.
    Shi H; Liu L; Wang Z
    Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CAR T-cell Therapy for Solid Tumors?
    Cancer Discov; 2018 Nov; 8(11):1341. PubMed ID: 30291124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imaging of T cells expressing chimeric antigen receptors.
    Roszik J; Rabinovich B; Cooper LJ
    Immunotherapy; 2011 Dec; 3(12):1411-4. PubMed ID: 22091674
    [No Abstract]   [Full Text] [Related]  

  • 40. Chimeric antigen receptor T cells: power tools to wipe out leukemia and lymphoma.
    Riet T; Abken H
    Expert Rev Hematol; 2015 Aug; 8(4):383-5. PubMed ID: 25946901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.